ライフサイエンスコーパス: recurrent UTI

1 28 (22%) in the placebo group had at least 1 recurrent UTI (difference, -6%; 95% confidence interval

2 elevated urinary calcium excretion (n = 2), recurrent UTI (n = 2), and urinary stasis (n = 2).

3 almost one-quarter of them will experience a recurrent UTI (rUTI).

4 (0.12 per person-year after first UTI) had a recurrent UTI.

5 entify the risk factors for resistance among recurrent UTIs.

6 ive and therapeutic approaches for acute and recurrent UTI.

7 is a significant risk factor for chronic and recurrent UTI.

8 iation between antimicrobial prophylaxis and recurrent UTI, and a nested case-control study was perfo

9 iation between antimicrobial prophylaxis and recurrent UTI, and to identify the risk factors for resi

10 d risk factor for chronic pyelonephritis and recurrent UTI in susceptible groups, even if it is outco

11 asymptomatic bacteriuria, to symptomatic and recurrent UTIs, to sepsis associated with UTI requiring

12 s could markedly reduce the rate of UTIs and recurrent UTIs.

13 ion of the prostate, typically presenting as recurrent UTIs from the same strain.

14 ecurrence rate among young women affected by recurrent UTI.

15 sylation and invasion of host cells to cause recurrent UTIs.

16 ostridium difficile, significantly decreased recurrent UTI frequency, and improved antibiotic suscept

17 iotic therapy, 30-50% of patients experience recurrent UTIs.

18 are isolated cases, 1 in 40 women experience recurrent UTIs.

19 lysis was used to determine risk factors for recurrent UTI and the association between antimicrobial

20 To identify risk factors for recurrent UTI in a pediatric primary care cohort, to det

21 iotic use is the most effective strategy for recurrent UTI prevention compared to daily cranberry pil

22 ions for the development of therapeutics for recurrent UTI.

23 Over 1.5 million women per year suffer from recurrent UTI, reducing quality of life and causing subs

24 Secondary endpoints included recurrent UTI within weeks 6 and 12 after day 1, rectal

25 r long-term urinary tract problems including recurrent UTI, vesicoureteral reflux, and renal scarring

26 nd in human stool from a study investigating recurrent UTI (rUTI).

27 rative effectiveness strategies for managing recurrent UTIs are lacking.

28 hiasis include retention of suture material, recurrent UTI, hypercalciuria, and urinary stasis.

29 However, recent data on the epidemiology of recurrent UTI (rUTI) are scarce.

30 linical samples from women with a history of recurrent UTI.

31 eveloped a Markov chain Monte Carlo model of recurrent UTI for each management strategy with >/=2 ade

32 each additional copy of DEFA1A3, the odds of recurrent UTI in patients receiving antibiotic prophylax

33 illi may be important in the pathogenesis of recurrent UTI by facilitating E. coli introital coloniza

34 ve nonantibiotic therapies for prevention of recurrent UTI (rUTI).

35 ecurrent UTI and antimicrobial resistance of recurrent UTI pathogens.

36 is was not associated with decreased risk of recurrent UTI (HR, 1.01; 95% CI, 0.50-2.02), even after

37 s, factors associated with increased risk of recurrent UTI included white race (0.17 per person-year;

38 substantially without affecting the risk of recurrent UTI or renal scarring.

39 is was not associated with decreased risk of recurrent UTI, but was associated with increased risk of

40 3 copy number did not associate with risk of recurrent UTI.

41 plications for understanding the etiology of recurrent UTIs.

42 ed 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatme

43 tric patients with VUR are the prevention of recurrent UTIs and minimizing the risk of renal scarring

44 and intravaginal routes in the prevention of recurrent UTIs.

45 may be a previously unappreciated source of recurrent UTIs and (ii) that inducing epithelial exfolia

46 (UT); however, since a significant subset of recurrent UTIs are caused by an identical bacterial stra

47 Patient-initiated treatment of recurrent UTIs may decrease antimicrobial use and improv

48 role of antibiotic prophylaxis in preventing recurrent UTI and renal scarring in young children with

49 membrane-enclosed latent reservoirs to seed recurrent UTI.

50 lar colonization resistance and cause severe recurrent UTI, which could be prevented by cyclooxygenas

51 reservoirs and are more prone to spontaneous recurrent UTI.

52 hildren were monitored for 1 year, and their recurrent UTIs were recorded.

53 increased susceptibility of nonsecretors to recurrent UTI.

54 the basis of understanding susceptibility to recurrent UTI in women.

55 dder remodeling, conveying susceptibility to recurrent UTI.

56 ease outcome, that impacts susceptibility to recurrent UTI.

57 Time to recurrent UTI and antimicrobial resistance of recurrent

58 can accurately self-diagnose and self-treat recurrent UTIs.

59 ltures were obtained from 140 women, 65 with recurrent UTI (case-patients) and 75 without (controls).

60 The presence of IBC/IIB was associated with recurrent UTI (odds ratio [OR], 3.3; 95% confidence inte

61 tibimicrobial resistance among children with recurrent UTI (HR, 7.50; 95% CI, 1.60-35.17).

62 trol study was performed among children with recurrent UTI to identify risk factors for resistant inf

63 d explain a high proportion of children with recurrent UTI.

64 One study of patients with recurrent UTI found that self-diagnosis significantly in

65 Sequential isolates from patients with recurrent UTI were classified, using macrorestriction an

66 ion, low DEFA1A3 copy number associated with recurrent UTIs in subjects in the RIVUR Study randomized

67 es and should be considered in patients with recurrent UTIs.

68 or for prophylaxis for menopausal women with recurrent UTIs.